A20对IL-17介导人牙周膜细胞RANKL表达影响

›› 2016, Vol. 36 ›› Issue (6): 489-493.

A20对IL-17介导人牙周膜细胞RANKL表达影响

叶宇¹,俞文伟¹,陈旭²,茅飞飞¹,徐艳³,李璐¹

1. 南京医科大学口腔疾病研究江苏省重点实验室
2. 江苏省口腔疾病研究重点实验室
3. 南京医科大学附属口腔医院牙周科

收稿日期:2015-12-24 修回日期:2016-02-27 出版日期:2016-06-28 发布日期:2016-06-30
通讯作者: 徐艳 E-mail:yanxu@njmu.edu.cn
基金资助:
国家自然科学基金;国家自然科学基金;江苏省高校优势学科建设工程

Effect of A20 on modulating RANKL expression of human periodontal ligament cells (hPDLCs) through IL-17

Received:2015-12-24 Revised:2016-02-27 Online:2016-06-28 Published:2016-06-30

摘要/Abstract

摘要： ［摘要］目的探究A20对IL-17调控人牙周膜细胞表面RANKL表达的影响。方法转染人牙周膜细胞（hPDLCs）A20siRNA、慢病毒，获得A20沉默/过表达hPDLCs，分为沉默组、正常组、过表达组，IL-17(50 ng/ml)刺激一定时间，ELISA，PCR ，Western-blot检测RANKL表达。结果 A20沉默组的hPDLCs RANKL蛋白表达水平较正常对照组高，A20过表达组较正常对照组低，IL-17（50ng/ml）刺激下，A20沉默组较正常对照组RANKL表达水平高，过表达组较正常对照组低。结论本研究首次发现A20可能参与调控IL-17引起的hPDLCs RANKL表达。

关键词: 牙周膜成纤维细胞, 白介素17 , 肿瘤坏死因子α诱导蛋白, 细胞核因子κB 受体活化因子配体

Abstract: Abstract: Objective To investigate the potential function of A20 on modulating RANKL expression of the human periodontal ligament cells (hPDLCs) regulated by IL-17. Methods HPDLCs were transfected of A20siRNA and slow virus, and then hPDLCs by suppression/over-expression of A20 were obtained, which were divided into suppression group, control group and over-expression group. Treated with IL-17 (50 ng/ml) for certain time, protein and mRNA levels of RANKL were determined by enzyme-linked immunosorbent assays (ELISA), real-time PCR (RT-PCR) and western blotting. Results Suppression/over-expression of A20 in hPDLCs increased/decreased the expression of RANKL protein compared to the control group. Upon the stimulation of IL-17 (50ng/ml), similar results were observed in the three groups of hPDLCs. Conclusion Our study revealed for the first time that IL-17 induced RANKL expression of hPDLCs may be interfered by A20.

Key words: periodontal ligament cells, IL-17, tumor necrosis factor alpha-induced protein3, RANKL

中图分类号:

R780.2

叶宇俞文伟陈旭茅飞飞徐艳李璐. A20对IL-17介导人牙周膜细胞RANKL表达影响[J]. , 2016, 36(6): 489-493.

参考文献

[1]Williams,R. C.Periodontal disease. The New England Journal of Medicine, 1990, 322:373–382.
[2] Onishi,R. M. & Gaffen, S. L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology, 2010, 129:311-321.
[3] Zhang FH, Tanaka T, Kawato S, Kitami K, Nakai M, Motohashi N, et al. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie, 2011, 93(2):296-305.
[4] Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor-associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med, 2000, 191:1233–1239.
[5] Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S.The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol, 2005, 32:369–374.
[6] Verdeil, G. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci U S A, 2014, 111:11115-11120
[7] Opipari AW Jr, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem, 1992, 267:12424 – 12427
[8] Song HY, Rothe M, Goeddel DV .The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NFkappaB activation. Proc Natl Acad Sci USA , 1996,93:6721 – 6725
[9]Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP et al. Failure to regulate TNFinduced NF-kappaB and cell death responses in A20-deficient mice. Science,2000, 289:2350–2354
[10]Garg, A. V., Ahmed, M., Vallejo, A. N., Ma, A. & Gaffen, S. L.The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal, 2013, 6, ra44
[11] Zhao L，Zhou Y，Xu Y，et al．Effect of non-surgical periodontal therapy on the levels of Th17 /Th1 /Th2 cytokines and their transcription factors in Chinese chronic periodontitis patients ［J］.JClin Periodontol,2011,38( 6):509-516．
[12]Lin, D., Li, L., Sun, Y., Wang, W., Wang, X., Ye, Y., Chen, X. & Xu, Y. IL-17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF6/TBK1-JNK/NF-kappaB pathways. Immunology ,2014,144:472–485
[13]Lee, Y. The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases.BMB Reports, 2013, 46:479-483
[14]Beklen, A., Ainola, M., Hukkanen, M., Gurgan, C., Sorsa,T. and Konttinen, Y. T. MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis.J. Dent. Res.2007,86:347-351.
[15]Balani, D., Aeberli, D., Hofstetter, W. & Seitz, M.Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro.Arthritis Rheum ,2013,65:436-446
[16]Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K.,Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N.,Gillespie, M. T., Martin, T. J. and Suda, T. IL-17 insynovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest.1999.103, 1345-1352.
[17]林丹萍,王威栋,李璐,等. IL-17对人牙周膜成纤维细胞RANKL表达的影响[J].口腔医学,2014,34(6):405-408.
[18]Weitzmann, M. N.The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) 2013, 125705
[19]Taubman MA, Kawai T, Han X. The new concept of periodontal disease pathogenesis requires new and novel therapeutic strategies.J Clin Periodontol, 2007, 34:367–369